Skip to content

The Study of Differences in Eosinophil Function and Subsets in Patients With Eosinophilic Pulmonary Diseases

The Study of Differences in Eosinophil Function and Subsets in Patients With Eosinophilic Pulmonary Diseases Based on Flow Cytometry Analysis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06944418
Enrollment
300
Registered
2025-04-25
Start date
2024-01-01
Completion date
2027-01-01
Last updated
2025-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eosinophilic Pulmonary Diseases, Eosinophil Subtype

Brief summary

The study subjects of this research are patients with eosinophil-associated pulmonary diseases, including eosinophilic granulomatosis with polyangiitis, idiopathic hypereosinophilic syndrome, idiopathic acute eosinophilic pneumonia, idiopathic chronic eosinophilic pneumonia, and primary simple pulmonary eosinophilia. The aim is to detect eosinophil subtypes in peripheral blood based on surface protein expression, to understand the differences in eosinophil subtypes among patients with different diseases, to elucidate the significance of different eosinophil subtypes, and ultimately to provide a theoretical basis for the selection of treatment directions for patients.

Interventions

OTHERobservation

observation

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* For Healthy Volunteers: healthy volunteers matching the age and gender of the study subjects * For EPD: ① Persistent eosinophil count increase\>1500 per cubic millimeter for more than 6 months. ② Lack of evidence of a secondary cause of eosinophilia is required. ③ Signs and symptoms of end-organ damage presumed to be secondary to eosinophilia

Exclusion criteria

* Patients with concurrent definitive pulmonary infections, malignancies, or other parenchymal lung diseases; * Patients who are unable or unwilling to cooperate with the collection of clinical information (e.g., due to mental disorders, memory impairments, etc.); * Patients who are unable to provide informed consent.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of Eosinophil Subtypes in SerumFrom January 1, 2024 to January 1, 2027Proportion of Eosinophil Subtypes in Serum Before and After Treatment in Patients

Countries

China

Contacts

Primary ContactJuhong Shi, M.D
shijh@pumch.cn+8613701178492

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026